The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big ...

Eli Lilly (NYSE: LLY) and Novo Nordisk(NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Fifty years ago, 20 of the world's brightest people tried to predict life in 2024. They got an awful lot wrong.

Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Last week, Eli Lilly reported earnings, provided some guidance that were below expectations due to underperformance in its Zepbound and Mounjaro weight loss and diabetes drugs. Asit, this week, ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...